Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges for gene therapy for muscular dystrophy.

Jerry R Mendell1, K Reed Clark

  • 1Center for Gene Therapy, Columbus Children's Research Institute, Columbus, OH 43205, USA. mendellj@ccri.net

Current Neurology and Neuroscience Reports
|February 14, 2006
PubMed
Summary

Gene therapy offers new hope for muscular dystrophy treatment. Adeno-associated viral vectors show promise, but challenges remain for clinical application of these gene-based therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.

Cardiology and therapy·2026
Same author

Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study.

Muscle & nerve·2026
Same author

Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management.

Human gene therapy·2026
Same author

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

Neurology and therapy·2026
Same author

High-Density Lipoprotein-Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin-Deficient Limb-Girdle Muscular Dystrophy Type R2.

Journal of cachexia, sarcopenia and muscle·2025
Same author

Limb-Girdle Muscular Dystrophy Scientific Workshop: A Multistakeholder Discussion Focused on Charting the Path Forward for Drug Development.

Neurology. Clinical practice·2025

Area of Science:

  • Biomedical research
  • Molecular biology
  • Genetics

Background:

  • Muscular dystrophy has limited treatment options.
  • Gene therapy is an emerging treatment strategy.
  • Adeno-associated viral vectors are key delivery systems.

Purpose of the Study:

  • Review recent advancements in gene therapy for muscular dystrophy.
  • Identify remaining challenges for clinical translation.
  • Provide an outlook on future gene-based treatments.

Main Methods:

  • Literature review of gene therapy research for muscular dystrophy.
  • Analysis of adeno-associated viral vector applications.
  • Discussion of clinical translation hurdles.

Main Results:

  • Gene therapy shows significant promise for muscular dystrophy.
  • Adeno-associated viral vectors have demonstrated success in research.
  • Clinical application faces hurdles including safety and efficacy.

Conclusions:

  • Gene therapy holds potential for treating muscular dystrophy.
  • Overcoming current challenges is crucial for clinical success.
  • Further research is needed to fully realize gene therapy's benefits.

Related Experiment Videos